Skip to Main Content

An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Conditions

Lymphoid Leukemia | Non-Hodgkin's Lymphoma | Phase I

Phase 1a/1b

What is the purpose of this trial?

This study is designed to evaluate the safety and pharmacokinetics of BTCT4465A when administered as a single agent by intravenous (IV) infusion to participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

  • Trial with
    Genentech, Inc.
  • Start Date
    05/02/2016
  • End Date
    10/30/2020
Trial Image

For more information about this study, contact:

Laura Leary

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    10/09/2018
  • Study HIC
    #1509016491